Sun, Jul 13, 2014, 11:45 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Zillow, Inc. Message Board

wcoastguy2008 48 posts  |  Last Activity: 23 hours ago Member since: Mar 16, 2009
  • "CYTK" - Cytokinectics - $160M market cap. - $4.46 currently.

    Company has the equivalent of 65% of its market cap in cash on hand and future milestone and royalty payments from Amgen and Astellas two pipeline drugs that could be seven times the current market cap.

    It really is that undervalued.

    p.s. Plus having the potential of a buyout offer at 2-3 times the current share price.

    Needham: $15.00 Price Target - Buy Rating

  • wcoastguy2008 by wcoastguy2008 May 2, 2014 10:10 AM Flag

    Brokerage are putting their clients in CYTK while its oversold. Expect the upgrades soon.

  • Reply to

    Penny Downside Versus Unlimited Upside

    by ambsadvocate May 1, 2014 1:46 PM
    wcoastguy2008 wcoastguy2008 May 2, 2014 9:35 AM Flag

    Zacks' analyst Jason Napadano says it's worth .24.

  • wcoastguy2008 by wcoastguy2008 May 2, 2014 9:30 AM Flag

    Interesting to note that $CYTK has the equivalent of 65% of its market cap in cash on hand and milestone and royalty payments that could be seven times the current market cap.

    It really is that undervalued.

    Just saying!!!

    p.s. Plus having the potential of a buyout offer at 2-3 times the current share price.

  • Overdue for news.

    Twitter: @AmarantusBio .... 9,928 followers.

  • wcoastguy2008 by wcoastguy2008 May 1, 2014 9:14 AM Flag

    Anticipating a very positive conference call. Update on milestone payments and news about the progress of the drugs in the pipeline.

    Current market cap: $160M versus potential milestone payments of over $1B plus royalties.

    Expecting the share price to be above $6.00 on Wednesday. Better days ahead. :)

    GLTA

    p.s. Shorts/bashers need shares to cover before this starts moving back above $10.00.

  • Amgen Inc. moved into Q2 2014 with $22.81 billion in cash and equivalents on its balance sheet.In the last year Amgen Inc. invested a reported $9.69 billion in company mergers and acquisitions.

    Amgen is working with Cytokinetics on omecamtiv mecarbil, a drug for the treatment of heart failure, a chronic condition responsible for the hospitalization of more than 1 million people in the U.S. every year.

    Omecamtiv mecarbil is currently in phase 2 trials seeking to demonstrate that the drug can boost heart muscle function and reduce hospital readmission.

    Amgen initially signed on for an option to work with Cytokinetics on the drug in 2006 when it paid the company $75 million upfront. Amgen executed that option in 2009, handing over another $50 million and taking on responsibility for development and commercialization in exchange for global rights to omecamtiv.

    Overall, Cytokinetics may receive up to $600 million in milestones from Amgen and double digit royalties.

    With Cytokinetics' market cap currently in the $160M range it seems that it makes perfect sense for Amgen to make a bid for the company.

    The corporate offices for the two companies make them neighbors already.

    Stranger things have happened.

    Just saying!!!

  • Amgen Inc. moved into Q2 2014 with $22.81 billion in cash and equivalents on its balance sheet.
    In the last year Amgen Inc. invested a reported $9.69 billion in company mergers and acquisitions.

    Amgen is working with Cytokinetics on omecamtiv mecarbil, a drug for the treatment of heart failure, a chronic condition responsible for the hospitalization of more than 1 million people in the U.S. every year.

    Omecamtiv mecarbil is currently in phase 2 trials seeking to demonstrate that the drug can boost heart muscle function and reduce hospital readmission.

    Amgen initially signed on for an option to work with Cytokinetics on the drug in 2006 when it paid the company $75 million upfront. Amgen executed that option in 2009, handing over another $50 million and taking on responsibility for development and commercialization in exchange for global rights to omecamtiv.

    Overall, Cytokinetics may receive up to $600 million in milestones from Amgen and double digit royalties.

    With Cytokinetics' market cap currently in the $160M range it seems that it makes perfect sense for Amgen to make a bid for the company.

    The corporate offices for the two companies make them neighbors already.

    Something to consider.

Z
131.18-0.24(-0.18%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Turtle Beach Corporation
NasdaqGMFri, Jul 11, 2014 4:00 PM EDT